- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06349512
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) (FAP-IT)
68Ga-FAPI-46 PET/CT for Predicting Histological Response to Neoadjuvant Chemo-immunotherapy in Triple-negative Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Prospective multicenter study evaluating the prediction of histological response of pembrolizumab in combination with neoadjuvant chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC.
Patients will receive the newly established standard of care of neoadjuvant pembrolizumab 200 mg Q3W given with 4 cycles of paclitaxel + carboplatin, then with 4 cycles of doxorubicin or epirubicin + cyclophosphamide. After definitive surgery, patients will receive adjuvant pembrolizumab for 9 cycles or until recurrence or unacceptable toxicity.
The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sandra Nespoulous
- Phone Number: 0147111654
- Email: drci.promotion@curie.fr
Study Contact Backup
- Name: Marie-Emmanuelle LEGRIER
- Phone Number: 0156245649
- Email: drci.promotion@curie.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female with age ≥ 18 years,
- Patients with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) for whom a neoadjuvant treatment with chemotherapy + pembrolizumab is the recommended option as standard of care,
- Patients with measurable targets according to RECIST/PERCIST criteria,
- Patients without distant metastasis based on staging 18F-FDG PET/CT,
- Patients with tumor tissue available,
- Patients who provided a signed written informed consent,
- Patient ability to comply with protocol requirements,
- Patients covered by a health insurance system.
Exclusion Criteria:
- Pregnant and lactating women,
- Patients with prior anti-PD(L)1 immunotherapy,
- Patients with any contra-indication to chemo-immunotherapy standard of care therapy, per investigator assessment,
- Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent,
- Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons,
- Patients who are not affiliated to a social security system, or who are deprived of liberty, or under guardianship.
- Person deprived of liberty or under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Triple Negative Breast Cancer
Patients with early-stage high-risk Triple Negative Breast Cancer
|
The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the ROC curve
Time Frame: 6 months
|
To measure the performance of 68Ga-FAPI-46 PET/CT imaging to predict complete histological response after neoadjuvant chemotherapy plus Pembrolizumab, in terms of Area under the ROC curve (AUC of the ROC curve).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT performances
Time Frame: Baseline
|
Detection of metastases (using the total number of metastatic lesion)
|
Baseline
|
Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT performances
Time Frame: Baseline
|
Evaluation of the tumor burden (using the total FAP expression tumor volume/TFTV* and the total metabolic tumor volume/TMTV*, respectively).
|
Baseline
|
Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT predictive performances
Time Frame: Baseline
|
Comparison of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT predictive performances, separately and combined.
|
Baseline
|
Evaluation of predictive model performance combining 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT
Time Frame: Baseline
|
Evaluation of predictive model performance combining 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT imaging data, using sensitivity, specificity, positive and negative predictive values and area under the ROC curve (AUC of the ROC curve)
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Romain-David SEBAN, Institut Curie
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IC 2022-07
- 2023-507860-37-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triple Negative Breast Cancer
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Swiss Group for Clinical Cancer ResearchNot yet recruitingTriple-negative Breast Cancer | TNBC - Triple-Negative Breast CancerSwitzerland
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH); MedImmune...TerminatedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | TNBC - Triple-Negative Breast Cancer | Triple-negative Breast CarcinomaUnited States
-
AkesoRecruitingMetastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast CancerChina
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
Fudan UniversityNot yet recruitingTriple-negative Breast Cancer
-
Fudan UniversityRecruitingTriple-Negative Breast CancerChina
-
Fudan UniversityRecruiting
-
Fudan UniversityRecruiting
Clinical Trials on 68Ga-FAPI-46 PET/CT imaging
-
Peter MacCallum Cancer Centre, AustraliaRecruitingCancer of Unknown Primary SiteAustralia
-
Maastricht University Medical CenterNot yet recruitingBreast Cancer | Breast Neoplasms | Breast DiseasesNetherlands
-
The First Affiliated Hospital of Xiamen UniversityCompletedTumor, Solid, FAPI, PET/CT, MetastasisChina
-
The National Center of Oncology, AzerbaijanSOFIE INCRecruitingBreast Neoplasms | Positron Emission Tomography | Fluorodeoxyglucose F18 | Fibroblast Activation Protein InhibitorAzerbaijan
-
Institut CurieRoche Pharma AG; National Research Agency, FranceNot yet recruitingTriple Negative Breast CancerFrance
-
Amsterdam UMC, location VUmcLeiden University Medical Center; Dutch Cancer SocietyRecruitingPancreatic Cancer | CholangiocarcinomaNetherlands
-
Karolinska University HospitalRecruitingStomach Neoplasms | Pancreatic Neoplasms | Epithelial Ovarian Cancer | Bile Duct NeoplasmsSweden
-
The First Affiliated Hospital of Xiamen UniversityRecruitingPrimary MyelofibrosisChina
-
Centre Hospitalier Intercommunal de Toulon La Seyne...Centre Antoine Lacassagne; Institut CurieRecruitingLobular Breast CarcinomaMonaco
-
Jonsson Comprehensive Cancer CenterProstate Cancer FoundationActive, not recruitingProstate Carcinoma | Recurrent Prostate Carcinoma | Metastatic Malignant Neoplasm in the Prostate GlandUnited States